Tus kws kho mob
QP36-17 Pharmacy Benefit Exclusion for Yescarta
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 07, 2017
Cov Ntaub Ntawv thiab Cov Txiaj Ntsig Ua Tau Los Ntawm Cov Foos
Nthuav pom cov txiaj ntsig tshwm sim 2941 - 2950 ntawm 3159
Tus kws kho mob
P65-17 Clarification to Commercial Prior Authorization for Biologic Immunomodulators
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P67-17 PA Requirements for New Medicare Advantage Prescription Drug Products in 2018
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P62-17 Addition of Drug to the Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P64-17 New Drug-Related PA with Quantity Limit Criteria: Biologic Immunomodulators
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P63-17 New Drug-Related PA with Quantity Limit Criteria: Otezla (apremilast)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P66-17 Clarification of Mid-Level Definitions
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P61-17 FQHC/RHC Clinics Providing Interpreter Services for MHCP Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 02, 2017
Tus kws kho mob
QP34-17 New Pre-Authorization Form for Immunoglobulin Therapy
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2017
Tus kws kho mob
P59-17 Government Programs Subscribers Prior Authorization Requirement for Spinal Fusion: Lumbar
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2017